{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:40:03Z","timestamp":1761154803030},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,8,25]],"date-time":"2005-08-25T00:00:00Z","timestamp":1124928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>We reviewed clinical and biologic findings in a series of infants with neuroblastoma (NB) in liver. The aim was to gain insights into improving therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Among 19 newly or recently diagnosed infants with NB in liver, 1987\u20132002, those with stage 4 involving bone received chemotherapy, while those without bone or extensive bone marrow (BM) involvement were observed or received limited treatment if NB caused life\u2010threatening symptoms. We assessed results in the context of NB treatment risk stratification, which is based on age, stage, and selected biologic features (<jats:italic>MYCN<\/jats:italic>, ploidy, histology).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six of eight infants with bone involvement became long\u2010term event\u2010free survivors including 1\/2 with <jats:italic>MYCN<\/jats:italic> amplification and four who received only 4\u20136 cycles of chemotherapy; at the end of treatment, four infants had abnormalities in liver\u2009\u00b1\u2009the primary site, but these resolved. All 11 infants without bone lesions became long\u2010term survivors with either no cytotoxic therapy or only one cycle of chemotherapy (\u00b1 radiotherapy to liver), including four who had stage 4 and one stage 4S patient who still had NB in BM at age 15 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Treatment reduction should be considered for subsets of infants with non\u2010<jats:italic>MYCN<\/jats:italic>\u2010amplified widespread NB: stage 4 without bone or extensive BM involvement may not require cytotoxic therapy, stage 4S with symptomatic hepatomegaly may not require multiple cycles of chemotherapy, and classic stage 4 may do well with limited chemotherapy. Persistent liver abnormalities post\u2010treatment may not require continued therapy to achieve a radiologic complete remission. \u00a9 2005 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20564","type":"journal-article","created":{"date-parts":[[2005,8,25]],"date-time":"2005-08-25T21:46:48Z","timestamp":1125006408000},"page":"278-284","source":"Crossref","is-referenced-by-count":14,"title":["Liver involvement in neuroblastoma: The memorial Sloan\u2010Kettering experience supports treatment reduction in young patients"],"prefix":"10.1002","volume":"46","author":[{"given":"Brian H.","family":"Kushner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"LaQuaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakeel","family":"Modak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nai\u2010Kong V.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-3-278"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1171"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1260"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1996.14.9.2504","article-title":"Successful management of low\u2010stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution","volume":"14","author":"Evans AE","year":"1996","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910143411601"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.8.1466"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2007"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199905000-00005"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.477"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(20001201)35:6<683::AID-MPO43>3.0.CO;2-F"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601154"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900915)66:6<1095::AID-CNCR2820660603>3.0.CO;2-0"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(20010101)36:1<227::AID-MPO1055>3.0.CO;2-U"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1256"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2821"},{"key":"e_1_2_5_17_2","first-page":"799","article-title":"Age as a continuous variable in predicting outcome for neuroblastoma patients with metastatic disease: Impact of tumor biological features","volume":"22","author":"George R","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_18_2","first-page":"800","article-title":"Favorable prognosis for patients ages 12\u201018 months with stage 4 MYCN\u2010nonamplified neuroblastoma","volume":"22","author":"Schmidt ML","year":"2003","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20564","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T10:02:43Z","timestamp":1696759363000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,25]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1002\/pbc.20564"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20564","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,25]]}}}